[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100416675":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":27,"responsibleParty":40,"collaborators":43,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":26,"enrollmentInfo":59,"targetDuration":26,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":75,"whyStopped":26,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Crete","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cretan IAMA (CAPeo)","EXPERIMENTAL","All patients are to receive Cretan IAMA (CAPeo) from Day 1.",[13],"Dietary Supplement: Cretan IAMA",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIETARY_SUPPLEMENT","Cretan IAMA","Cretan IAMA (CAPeo) soft gels, 1 ml\u002Fday of a 1.5% essential oil combination from three aromatic plants (Thymbra 59 capitata (L.) Cav., Origanum dictamnus L., Salvia fruticosa Mill.) in extra virgin olive oil",[9],[21],"CAPeo",[23],{"name":24,"affiliation":5,"role":25},"Christos Lionis","PRINCIPAL_INVESTIGATOR",null,[28],{"facility":29,"status":26,"city":30,"state":31,"zip":26,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":26},"Cretan Medicare","Heraklion","Crete","Greece","GR",{"type":35,"coordinates":36},"Point",[37,38],25.14341,35.32787,{"lat":38,"lon":37},{"type":25,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Christor Lionis","Professor of General Practice and Primary Healthcare, Director of the Clinic of Social and Family Medicine",[44,47],{"name":45,"class":46},"Galenica SA","UNKNOWN",{"name":48,"class":46},"Olvos Science SA","100416675","phase-2-assessment-of-the-clinical-effectiveness-of-a-herbal-extract-cretan-iama-in-patients-with-viral-respiratory-infections-including-covid-19-in-primary-healthcare-settings-and-co-assessment-of-its-prophylactic-effect-in-people-cohabiting-with-these-patients-100416675",false,"NCT04705753","Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients","Evaluation of the Clinical Outcomes and the Quality of Life of Patients Exhibiting Symptoms Characteristic of Viral Respiratory Infection (VRI), Including Infection by SARS-CoV-2 (COVID-19), and Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in These Patients and the People Cohabiting With Them Via an Open-label, Single-arm Trial","COVID-19-IAMA","Inclusion Criteria:\n\n* For the patients:\n\n  * Any woman or man requesting a home visit and having symptoms characteristic of viral infection, with initial manifestation within the previous 48-72 hrs. Such symptoms may include sudden fever onset, accompanied by one or more of the following symptoms: dry cough, sore throat, nasal congestion, headache, musculoskeletal pain, perspiration, fatigue, malaise, blurry vision, loss of the sense of smell.\n* For the people cohabiting with patients:\n\n  * Any woman or man cohabiting with study patients.\n\nExclusion Criteria:\n\n* Children and adolescents under the age of 18 years;\n* Pregnant women;\n* Persons suffering from a pre-existing condition preventing them from autonomously providing informed consent.","ALL","18 Years",{"count":60,"type":61},20,"ACTUAL","INTERVENTIONAL",[64,65],"PHASE2","PHASE3","This single-arm, open-label small interventional proof-of-concept (POC) study study aims:\n\n1. to assess the clinical outcomes of patients exhibiting viral respiratory infection (VRI) symptoms and seeking primary healthcare (PHC) services at the time of the COVID-19 pandemic,\n2. to assess the clinical effectiveness of the Cretan IAMA (CAPeo), a herbal extract combination, for these patients, including in terms of symptom resolution (symptom frequency, duration) and intensity), and\n3. to investigate its prophylactic effect in terms of transmission prevention for people cohabiting with the patients exhibiting VRI symptoms.",[68,69,70],"Covid19","Viral Infection","Respiratory Viral Infection",[72,73,74],"Infectious disease","Herbal Medicine","Botanical Medicine","COMPLETED","2021-01-11",{"date":78,"type":61},"2021-01-12",{"date":80,"type":61},"2020-04-01",{"date":82,"type":61},"2020-10-15",{"name":5,"class":6},1]